Document is current
Any future updates will be listed below
-
Authors
Du Rietz, Ebba https://orcid.org/0000-0002-3427-0792
Xie, Tian https://orcid.org/0000-0003-2442-7941
Wang, Rujia https://orcid.org/0000-0003-2574-990X
Cheesman, Rosa
Garcia-Argibay, Miguel https://orcid.org/0000-0002-4811-2330
Dong, Zihan
Zhang, Jia
Niebuur, Jacobien
Vos, Melissa https://orcid.org/0000-0002-4777-6338
Snieder, Harold https://orcid.org/0000-0003-1949-2298
Larsson, Henrik
Hartman, Catharina A. https://orcid.org/0000-0002-8094-8859
-
Funding
Funding for this research was provided by:
Svenska Sällskapet för Medicinsk Forskning (PD20-0036)
Fredrik och Ingrid Thurings Stiftelse (2021-00638)
Norges Forskningsråd (288083)
Vetenskapsrådet (2018-02599, 2022-01119)
- License Information
-
More Information
Article History
Received: 17 November 2023
Revised: 14 October 2024
Accepted: 5 November 2024
First Online: 13 November 2024
Competing interests
: EDR has served as a speaker for Shire Sweden AB, a Takeda Pharmaceutical Company outside of this work. HL reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; all outside the submitted work. HL is editor-in-chief of JCPP Advances.
